Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabián P Alvarez

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|May 23, 2006
Epidemic variability in complex networksPascal Crépey, Fabián P Alvarez, Marc Barthélemy
Vaccine|February 1, 2021
Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature reviewFlorian Colrat, Edward Thommes, Nathalie Largeron, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|June 29, 2011
[On the viability of introducing the inactivated polio vaccine in Colombia]Fabián P Alvarez, José Alejandro Mojica, Carlos Espinal, et al.
Influenza and Other Respiratory Viruses|February 5, 2022
The economic burden of influenza among adults aged 18 to 64: A systematic literature reviewCaroline de Courville, Sarah M Cadarette, Erika Wissinger, et al.
Human Vaccines & Immunotherapeutics|September 22, 2020
Cost-effectiveness analysis has to consider all available evidence when informing inputsFabián P Alvarez, Audrey Petitjean, Joshua Nealon, et al.
Frontiers in Public Health|November 29, 2023
Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult populationFilippo Rumi, Michele Basile, Americo Cicchetti, et al.
Vaccine|January 29, 2021
Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United StatesPierre Net, Florian Colrat, Mafalda Nascimento Costa, et al.
Journal of Medical Economics|November 2, 2021
Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and WalesRichard Mattock, Ilana Gibbons, Joe Moss, et al.
Journal of Medical Economics|July 31, 2025
A systematic review of health state utility values for influenza and influenza-like illnessRia Heinrich, Franziska Sende, Josephine Thiesen, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 8, 2024
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020Caroline de Courville, Hélène Bricout, Fabián P Alvarez, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|May 23, 2006
Epidemic variability in complex networksPascal Crépey, Fabián P Alvarez, Marc Barthélemy
Vaccine|February 1, 2021
Economic evaluation of high-dose inactivated influenza vaccine in adults aged ≥65 years: A systematic literature reviewFlorian Colrat, Edward Thommes, Nathalie Largeron, et al.
Revista Panamericana De Salud Publica = Pan American Journal of Public Health|June 29, 2011
[On the viability of introducing the inactivated polio vaccine in Colombia]Fabián P Alvarez, José Alejandro Mojica, Carlos Espinal, et al.
Influenza and Other Respiratory Viruses|February 5, 2022
The economic burden of influenza among adults aged 18 to 64: A systematic literature reviewCaroline de Courville, Sarah M Cadarette, Erika Wissinger, et al.
Human Vaccines & Immunotherapeutics|September 22, 2020
Cost-effectiveness analysis has to consider all available evidence when informing inputsFabián P Alvarez, Audrey Petitjean, Joshua Nealon, et al.
Frontiers in Public Health|November 29, 2023
Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult populationFilippo Rumi, Michele Basile, Americo Cicchetti, et al.
Vaccine|January 29, 2021
Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United StatesPierre Net, Florian Colrat, Mafalda Nascimento Costa, et al.
Journal of Medical Economics|November 2, 2021
Cost-effectiveness of high dose versus adjuvanted trivalent influenza vaccines in England and WalesRichard Mattock, Ilana Gibbons, Joe Moss, et al.
Journal of Medical Economics|July 31, 2025
A systematic review of health state utility values for influenza and influenza-like illnessRia Heinrich, Franziska Sende, Josephine Thiesen, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 8, 2024
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020Caroline de Courville, Hélène Bricout, Fabián P Alvarez, et al.
Pageof 2